Startups

Booster Therapeutics

Berlin, Germany

Booster Therapeutics GmbH is a Berlin biotechnology company developing small molecules that directly activate20Sproteasomes, the cellular protein quality-control machinery, with an initial focus on neurodegenerative proteinopathies including Parkinson’s and Alzheimer’s disease. Its DGRADX platform combines automated high-throughput screening, structural methods including X-ray crystallography and computational tools; machine learning is not independently verified, so it is not taggedAI solely from computational branding. Direct proteasome activation is distinguished from lysosomal degradation and ubiquitin-directed26Sproteasome mechanisms. Its stated therapeutic effects are investigational research hypotheses, not established human clinical benefit or regulatory approval. The founder’s own MJFF biography dates inception to2020; the public launch and actualUSD15Mseedfinancing were October10,2024. Scientific founders are Diogo Feleciano and Darci Trader, alongside Apollo’s venture-creation platform. Exact legal disclosure identifies BoosterTherapeuticsGmbH, HRB220166, AmtsgerichtCharlottenburg. Its public directory names seven scientific/operating/advisory people and four board members with one overlap. A2025USD5Mresearchgrant award is separately qualified because paid-to-date/disbursement evidence is not published.

Founded 2020